Metrics to compare | DEXTECH | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipDEXTECHPeersSector | |
|---|---|---|---|---|
P/E Ratio | −31.0x | 15.7x | −0.3x | |
PEG Ratio | 0.93 | −0.18 | 0.00 | |
Price/Book | 9.4x | 6.9x | 2.6x | |
Price / LTM Sales | 45.6x | 12.1x | 3.1x | |
Upside (Analyst Target) | - | 155.5% | 49.0% | |
Fair Value Upside | Unlock | 5.0% | 6.3% | Unlock |
Dextech Medical AB engages in the development of drug candidates with application in urological oncology, primarily prostate cancer in Sweden. The company’s lead candidate, OsteoDex, which has completed a phase IIb clinical trial for the treatment of bone metastases in castration-resistant prostate cancer, as well as in preclinical stage to treat breast and lung cancer, as well as multiple myeloma. The company is also developing SomaDex, a medication candidate that is based on an endogenous hormone, somatostatin, or the treatment of acromegaly, neuroendocrine tumors, and palliative care in advanced prostate cancer; and PSMA-binding conjugates for the target-specific treatment of mCRPC that overexpresses prostate specific membrane antigen (PSMA). In addition, the company offers GuaDex (formarly CatDex), a technology platform and a charge-modified dextran molecule with tumor-toxic properties used for medication development. Dextech Medical AB was incorporated in 2004 and is based in Uppsala, Sweden.